Research Paper Volume 13, Issue 14 pp 18423—18441

Figure 2. YJD treatment reduces inflammation in the nasal mucosal tissues of AR model guinea pigs. (A) Toluidine blue staining of nasal mucosal samples from control, AR model, AR model plus YJD, and AR model plus dexamethasone groups. (B) The histogram plots show the percentage of mast cells in the nasal mucosal samples from the control, AR model, AR model plus YJD, and AR model plus dexamethasone groups based on toluidine blue staining. The samples were analyzed independently by 3 pathologists based on five different staining views. *P < 0.05; **P < 0.01; one-way ANOVA. (C) IHC staining of nasal mucosal samples from control, AR model, AR model plus YJD treatment, and AR model plus dexamethasone treatment groups using the anti-TGF-β antibody (magnification: 200×). IgG staining was used as negative control. (D) The histogram plots show average optical density (AOD) of TGF-β expression in the nasal mucosal samples from control, AR model, AR model plus YJD, and AR model plus dexamethasone groups. *P < 0.05; **P < 0.01; one-way ANOVA.